Analgesic Additives to Epidural Bupivacaine in Normal Labor

Sponsor
Assiut University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05746351
Collaborator
(none)
69
3
28

Study Details

Study Description

Brief Summary

The aim of the study will be to compare the role of Dexmedetomidine, Nalbuphine and fentanyl as additives to epidural bupivacaine in painless vaginal delivery as regard of effectiveness analgesia and maternal safety.

Condition or Disease Intervention/Treatment Phase
N/A

Detailed Description

Labor pain often causes a strong stress response. Several inhalation and parenteral anesthetics, sedatives, tranquilizers, and analgesics have been used for pain relief during labor, while over the last decade, lumbar epidural analgesia has greatly increased .

Recently, it was concerned by most mothers and doctors that how to alleviate the pain during delivery. The ideal labor analgesia should be based on maternal and child safety and should have a fast acting good analgesic effect and less adverse reaction .

Epidural anesthesia is convenient and has a less adverse reaction and obvious effect in the commonly used analgesic methods, which are widely used in the current way of analgesia .

Studies have confirmed the efficacy of dexmedetomidine in prolonging the duration of perineural nerve blocks. Specifically, perineural dexmedetomidine enhances sensory, motor, and analgesic block characteristics.

Dexmedetomidine is a selective α₂ receptor agonist and has a sympatholytic, sedative, and opioid sparing effect. It does not cause respiratory depression and can therefore be used as an adjuvant in certain clinical settings .

It has also been proved that dexmedetomidine would not increase the risk of side effects, such as nausea, headache, vomiting, shivering, and hypotension .

Nalbuphine is a synthetic agonist-antagonist opioid that has the characteristics of Mu-antagonist and Kappa-agonist activities. Nalbuphine has gained parenteral analgesia for intraoperative, postoperative, and obstetrical uses .

The analgesic potency of nalbuphine has been found to be equal to morphine, but unlike morphine, it shows a ceiling effect on respiratory depression. It has the potential to provide effective postoperative analgesia with no risk of respiratory depression .

Study Design

Study Type:
Interventional
Anticipated Enrollment :
69 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
The participants will be divided into three equal groups ,one group will receive epidural analgesia with bupivacaine and dexmedetomidine, another Group will receive epidural analgesia with bupivacaine and fentanyl and the other Group will receive epidural analgesia with bupivacaine and Nalbuphine.The participants will be divided into three equal groups ,one group will receive epidural analgesia with bupivacaine and dexmedetomidine, another Group will receive epidural analgesia with bupivacaine and fentanyl and the other Group will receive epidural analgesia with bupivacaine and Nalbuphine.
Masking:
None (Open Label)
Primary Purpose:
Supportive Care
Official Title:
Dexmedetomidine , Fentanyl or Nalbuphine As Additives to Epidural Bupivacaine for Labor Analgesia. A Double Blind Randomized Study.
Anticipated Study Start Date :
Mar 1, 2023
Anticipated Primary Completion Date :
Mar 1, 2025
Anticipated Study Completion Date :
Jul 1, 2025

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: epidural Bupivacaine with Dexmedetomidine in normal labor

Epidural analgesia will be initiated and maintained using a solution of 0.125% bupivacaine with Dexmedetomidine 0.5 μg/ml

Drug: Dexmedetomidine
a group will receive epidural Bupivacaine with Dexmedetomidine in normal labor
Other Names:
  • precedex
  • Active Comparator: epidural Bupivacaine with fentanyl in normal labor

    Epidural analgesia will be initiated and maintained using a solution of 0.125% bupivacaine with fentanyl 2 μg/ml.

    Drug: fentanyl
    a group will receive epidural Bupivacaine with fentanyl in normal labor
    Other Names:
  • Durogesic
  • Active Comparator: epidural Bupivacaine with Nalbuphine in normal labor

    Epidural analgesia will be initiated and maintained using a solution of 0.125% bupivacaine with 0.2 mg/ml Nalbuphine.

    Drug: Nalbuphine
    a group will receive epidural Bupivacaine with Nalbuphine in normal labor
    Other Names:
  • Nalufin
  • Outcome Measures

    Primary Outcome Measures

    1. VAS score for pain [before epidural analgesia, 30 minutes from time 0, at 1 hour and hourly till end of 3rd stage of delivery.]

      changes in VAS score for pain before epidural analgesia, 30 minutes from time 0, at 1 hour and hourly till end of 3rd stage of delivery.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 40 Years
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • /= 18 years of age

    • American Society of Anesthesiologists (ASA) Physical Status 2 or 3

    • Full term pregnancy (>37 gestational weeks)

    • Planning vaginal delivery

    • Planning epidural labor analgesia

    • Vertex presentation

    Exclusion Criteria:
    • Patient refusal to epidural analgesia,

    • Contraindications of epidural analgesia (coagulopathy, local infection, vertebral deformity)

    • Allergy to study agents (hypersensitivity to bupivacaine, Nalbuphine, fentanyl or dexmedetomidine)

    • hemodynamic instability, severe aortic or mitral stenosis)

    • Severe pre-eclampsia,

    • Breech presentations

    • Antepartum hemorrhage

    • Cephalopelvic disproportion

    • Body mass index ≥40 kg/m2.

    • Uncontrolled systemic comorbidities [i.e., diabetes, hepatic, renal or cardiac]

    • Known or suspected fetal abnormalities

    • Inability to communicate or participate in study procedures

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • Assiut University

    Investigators

    • Study Chair: Zein EA Zareh Hassan, professor, Assiut University
    • Study Director: Elwani Eldramy Elsenosi, professor, Assiut University
    • Principal Investigator: Khaled Tolba Younes, Lecturer, Assiut University

    Study Documents (Full-Text)

    None provided.

    More Information

    Additional Information:

    Publications

    None provided.
    Responsible Party:
    Abanob Fathy Zareef, Resident, Assiut University
    ClinicalTrials.gov Identifier:
    NCT05746351
    Other Study ID Numbers:
    • epidural additives in labor
    First Posted:
    Feb 27, 2023
    Last Update Posted:
    Feb 27, 2023
    Last Verified:
    Feb 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Abanob Fathy Zareef, Resident, Assiut University
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Feb 27, 2023